---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-24-000026"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2024-07-25T23:59:59+00:00"
generated_at: "2026-05-31T16:16:52.456693+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AbbVie Q2 adj EPS $2.65, revenue $14.46B; raises FY2024 adj EPS guidance to $10.71-$10.91

## Summary
- Q2 GAAP EPS $0.77 (down 32.5% YoY); adjusted EPS $2.65 (down 8.9% YoY), including $0.52 IPR&D impact.
- Net revenue $14.462B (+4.3% reported, +5.6% operational); Immunology up 2.3% as Humira -29.8% offset by Skyrizi +44.8% and Rinvoq +55.8%.
- Neuroscience portfolio up 14.7% to $2.162B; Aesthetics flat at $1.390B.
- FY2024 adjusted EPS guidance raised to $10.71-$10.91 from $10.61-$10.81, including $0.60 IPR&D impact.
- Recent events: Robert Michael became CEO July 1; FDA approved Skyrizi for UC; FDA CRL for ABBV-951 Parkinson's; acquisitions of Landos and Celsius.

## SEC filing metadata
- accession: 0001551152-24-000026
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2024-07-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000026/0001551152-24-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000026/abbv-20240725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-24-000026
- JSON: https://secwatch.observer/filing/0001551152-24-000026.json
- Plain text: https://secwatch.observer/filing/0001551152-24-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.